Biologics Market Forecast Highlights Expansion From $540.46 Billion To $827.24 Billion Through 2030
Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Biologics Market Size Forecast: How Large Could The Market Become By 2030?
The scale of the biologics market has experienced robust expansion over recent years. Projected to increase from $495.56 billion in 2025 to $540.46 billion in 2026, this represents a compound annual growth rate (CAGR) of 9.1%. This past period’s growth can be traced to such factors as the restricted access to biologics, a dependence on conventional treatments, a rising frequency of immune-related conditions, improvements in healthcare systems, and greater awareness among doctors leading to more prescriptions.
The biologics market is projected to experience robust expansion in the coming years, reaching an estimated $827.24 billion by 2030 with a compound annual growth rate (CAGR) of 11.2%. This anticipated growth during the forecast period is driven by factors such as the creation of innovative monoclonal antibodies, the broadening use of mRNA and viral vector vaccines, rising uptake of customized biologic treatments, heightened governmental backing and investment in biologics, and the incorporation of digital health tools along with patient monitoring systems. Key trends shaping this period include the growing utilization of monoclonal antibodies and therapeutic proteins, progress in vaccine development with mRNA and viral vector platforms, the broadening of prescription-based biologics and hospital pharmacy distribution, a heightened emphasis on personalized medicine and focused biologic therapies, and the merging of biologics with state-of-the-art healthcare solutions and ongoing patient monitoring.
Download A Free Sample Report For Comprehensive Market Insights:
Biologics Market Demand Drivers: What Is Fueling Industry Growth?
The growing need for tailored medical treatments is fueling considerable expansion in the worldwide biologics market. Personalized medicine, commonly referred to as precision medicine, represents a healthcare strategy that customizes medical care and therapeutic interventions according to each patient’s unique attributes. This approach enables the adaptation of biologic therapies to match a person’s distinct genetic and clinical profile, thereby reshaping the medical field. As an example, the Personalized Medicine Coalition, a US-based hospital and healthcare organization, reported in February 2024 that the FDA approved 16 new personalized therapies for rare diseases in 2023, a notable rise from six approvals in 2022. Consequently, the heightened demand for personalized medicine continues to propel the growth of the biologics market in the years ahead.
Biologics Market Segment Breakdown: Which Categories Generate The Most Revenue?
The biologics market covered in this report is segmented –
1) By Type: Monoclonal Antibodies (MAbS), Therapeutic Proteins, Vaccines
2) By Drug Classification: Branded Drugs, Generic Drugs
3) By Route Of Administration: Oral, Other Route Of Administration
4) By Mode Of Purchase: Prescription-Based Drugs, Over-The-Counter Drugs
5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies Or Drug Stores, Other Distribution Channels
Subsegments:
1) By Monoclonal Antibodies (MAbs): Naked Monoclonal Antibodies, Conjugated Monoclonal Antibodies, Bispecific Monoclonal Antibodies
2) By Therapeutic Proteins: Hormones, Enzymes, Cytokines, Fusion Proteins
3) By Vaccines: Live Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, mRNA Vaccines, Viral Vector Vaccines
Biologics Market Innovation Trends: Which Developments Are Transforming The Industry?
Key players in the biologics market are actively creating advanced products like biosimilars, which serve as cost-efficient options compared to original biologic treatments. Biosimilars represent biologic agents that closely resemble an already licensed reference biologic, exhibiting no substantial variations in safety, efficacy, or quality, thereby contributing to lower therapy expenses and improved patient availability of cutting-edge treatments. For example, during July 2025, Biocon Biologics, a division of Biocon Limited (a biopharmaceutical firm headquartered in India), introduced Nepexto, which is a biosimilar for Enbrel (etanercept), within Australia. This product, a fusion-protein biologic, is intended to block tumor necrosis factor-alpha (TNF-a), a crucial factor in inflammation for autoimmune disorders. It incorporates a protein generated via recombinant DNA technology that replicates the binding properties of the original etanercept molecule, offering equivalent effectiveness and safety while boosting treatment affordability. Notable attributes of Nepexto include a high degree of biosimilarity, validated by comprehensive clinical evidence, regulatory clearances, and a dependable distribution system through its local collaborator Generic Health, positioning it as a solid choice for the sustained management of conditions such as rheumatoid arthritis, psoriasis, and ankylosing spondylitis.
Biologics Market Key Players And Strategic Industry Positioning
Major companies operating in the biologics market are Merck & Co. Inc., AbbVie Inc., F. Hoffmann-La Roche AG, Johnson & Johnson, Pfizer Inc., Bristol Myers Squibb Company, Sanofi S.A., GlaxoSmithKline Plc., Eli Lilly and Company, Amgen Inc., Shanghai Fosun Pharmaceuticals, Bayer AG, Novartis AG, BiosanaPharma, WuXi, Teva UK Limited, AstraZeneca, Abbott Laboratories, Vectura Group, Fujifilm, Lonza, Seqens, Piramal Pharma Solutions, Corden Pharma, Procos SpA and BSP Pharmaceuticals., Microgen, Geropharm, Valenta, NovaMedica, SynBi, Rani Therapeutics, Enteris BioPharma, Allena Pharmaceuticals, Biogen Inc., Emisphere Technologies Inc., Apotex, Gilead Sciences
Access The Complete Biologics Market Report:
Biologics Market Regional Outlook: Where Are The Largest Opportunities Located?
North America was the largest region in the biologics market in 2025. Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the biologics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
